DEXOLIGO Trademark
Trademark Overview
On Wednesday, August 2, 2023, a trademark application was filed for DEXOLIGO with the United States Patent and Trademark Office. The USPTO has given the DEXOLIGO trademark a serial number of 79384444. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, November 26, 2024. This trademark is owned by Dexcel Pharma Technologies Ltd.. The DEXOLIGO trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations, namely, oligonucleotides, siRNA and antisense RNA for use in the treatment of cancer, hepatitis, neurodegenerative diseases, neurological diseases, hemophilia, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, rare bleeding disorders, iron overload disorders, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, chronic liver infection, anemia, myeloproliferative disorders, auto-immune disorders, chronic kidney diseases, obesity, type 2 diabetes, metabolic syndrome and related conditions, thrombocythemia, gout
General Information
| Serial Number | 79384444 |
| Word Mark | DEXOLIGO |
| Filing Date | Wednesday, August 2, 2023 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, November 26, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, November 26, 2024 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations, namely, oligonucleotides, siRNA and antisense RNA for use in the treatment of cancer, hepatitis, neurodegenerative diseases, neurological diseases, hemophilia, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, rare bleeding disorders, iron overload disorders, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, chronic liver infection, anemia, myeloproliferative disorders, auto-immune disorders, chronic kidney diseases, obesity, type 2 diabetes, metabolic syndrome and related conditions, thrombocythemia, gout |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, December 8, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Dexcel Pharma Technologies Ltd. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | IL |
| Party Name | Dexcel Pharma Technologies Ltd. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | IL |
Trademark Events
| Event Date | Event Description |
| Thursday, December 7, 2023 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, December 8, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, December 12, 2023 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, April 3, 2024 | ASSIGNED TO EXAMINER |
| Monday, April 8, 2024 | NON-FINAL ACTION WRITTEN |
| Tuesday, April 9, 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Wednesday, April 24, 2024 | REFUSAL PROCESSED BY MPU |
| Wednesday, April 24, 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Tuesday, May 14, 2024 | REFUSAL PROCESSED BY IB |
| Tuesday, October 15, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, October 15, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, October 16, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, October 31, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, November 20, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, November 26, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, November 26, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
